Currently Closed – We are no longer accepting or processing applications for new or renewal patients.
The PAN Foundation’s Renal Cell Carcinoma fund is currently closed. As of June 12, 2019, CancerCare's Renal Cell Cancer fund is accepting applications.
For current information, log in to FundFinder.
$5,900 per year. Patients may apply for a second grant during their eligibility period subject to availability of funding.
- The patient must be getting treatment for renal cell carcinoma.
- The patient must have Medicare health insurance that covers his or her qualifying medication or product.
- The patient’s medication or product must be listed on PAN’s list of covered medications.
- The patient’s income must fall at or below 500% of the Federal Poverty Level.
- The patient must reside and receive treatment in the United States or U.S. territories. (U.S. citizenship is not a requirement.)
See the list of medications covered in this program
- Adriamycin (doxorubicin hcl)
- Afinitor (everolimus)
- Avastin (bevacizumab)
- Bavencio (avelumab)
- Cabometyx (cabozantinib s-malate)
- Carboplatin (carboplatin)
- Cisplatin (cisplatin)
- Doxorubicin Hcl (doxorubicin hcl)
- Erlotinib Hcl (erlotinib hcl)
- Gemcitabine Hcl (gemcitabine hcl)
- Gemzar (gemcitabine hcl)
- Inlyta (axitinib)
- Intron A (interferon alfa-2b,recomb.)
- Keytruda (pembrolizumab)
- Lenvima (lenvatinib mesylate)
- Nexavar (sorafenib tosylate)
- Opdivo (nivolumab)
- Paclitaxel (paclitaxel)
- Prednisone (prednisone)
- Proleukin (aldesleukin)
- Sutent (sunitinib malate)
- Tarceva (erlotinib hcl)
- Torisel (temsirolimus)
- Votrient (pazopanib hcl)
- Yervoy (ipilimumab)
- Zortress (everolimus)
ICD-10: C64.1, C64.2, C64.9
About the Disease:
Renal cell carcinoma (RCC), also known as kidney failure, kidney cancer and renal adenocarcinoma, is a type of kidney cancer that starts in the lining of the kidneys. RCC affects the exocrine system.
Source: National Institutes of Health